Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial.
Sinha SD, Bandi VK, Bheemareddy BR, Thakur P, Chary S, Mehta K, Pinnamareddy VR, Pandey R, Sreepada S, Durugkar S. Sinha SD, et al. Among authors: durugkar s. BMC Nephrol. 2019 Nov 19;20(1):415. doi: 10.1186/s12882-019-1515-7. BMC Nephrol. 2019. PMID: 31744458 Free PMC article.
Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial.
Mehta KS, Sinha SD, Vamsi B, Reddy B, Naidu NR, Thakur PA, Sreenivasa C, Reddy VPR, Pandey R, Durugkar S. Mehta KS, et al. Among authors: durugkar s. J Assoc Physicians India. 2019 Jan;67(1):62-66. J Assoc Physicians India. 2019. PMID: 30935177 Clinical Trial. No abstract available.
Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial.
Sinha SD, Bandi VK, Bheemareddy BR, Thakur P, Chary S, Mehta K, Pinnamareddy VR, Pandey R, Sreepada S, Durugkar S. Sinha SD, et al. Among authors: durugkar s. BMC Nephrol. 2019 Mar 13;20(1):90. doi: 10.1186/s12882-019-1209-1. BMC Nephrol. 2019. PMID: 30866856 Free PMC article. Clinical Trial.
Is survival enough for quality of life in Sagliker Syndrome-uglifying human face appearances in chronic kidney disease?
Sagliker Y, Acharya V, Golea O, Sabry A, Bali M, Eyupoglu K, Ookalkar D, Tapiawala S, Durugkar S, Khetan P, Capusa C, Univar R, Yildiz I, Cengiz K, Akar H, Yenicerioglu Y, Sagliker Ozkaynak P, Sabit Sagliker H, Paylar N. Sagliker Y, et al. Among authors: durugkar s. J Nephrol. 2008 Mar-Apr;21 Suppl 13:S134-8. J Nephrol. 2008. PMID: 18446747
International study on Sagliker syndrome and uglifying human face appearance in severe and late secondary hyperparathyroidism in chronic kidney disease patients.
Sagliker Y, Acharya V, Ling Z, Golea O, Sabry A, Eyupoglu K, Ookalkar DS, Tapiawala S, Durugkar S, Khetan P, Capusa C, Univar R, Yildiz I, Cengiz K, Bali M, Ozkaynak PS, Sagliker HS, Paylar N, Adam SM, Balal M, Paydas S, Demirhan O, Tasdemir D, Ben Maiz H, Redulescu D, Garneata L, Mircescu G, Hong-Liang R, Lun L, Yildizer K, Emir I, Yuksekgonul M, Yenicerioglu Y, Akar H, Sagliker C, Esenturk M, Kiralp N. Sagliker Y, et al. Among authors: durugkar s. J Ren Nutr. 2008 Jan;18(1):114-7. doi: 10.1053/j.jrn.2007.10.023. J Ren Nutr. 2008. PMID: 18089456